Literature DB >> 6772264

Antigen-induced bronchial anaphylaxis in actively sensitized guinea-pigs: anti-anaphylactic effects of sodium cromoglycate and aminophylline.

P Andersson.   

Abstract

1 The inhibitory effects of sodium cromoglycate (SCG) and aminophylline on antigen-induced bronchial anaphylaxis in guinea-pigs, actively sensitized according to different regimens, were examined. 2 SCG (1 mg/kg administered intravenously) reduced the anaphylactic response in animals sensitized with 1 microgram ovalbumin (OA) together with A1(OH)3 100 mg, and challenged at 14 and 40 days after sensitization. If higher doses of antigen (10 micrograms OA together with A1(OH)3 or 5 mg OA on day 0 plus 10 mg OA on day 2) were used for sensitization, the protective effect of SCG was found only in animals tested 14 days after sensitization. 3 A low dose of aminophylline (0.3 mg/kg) that was without a direct bronchodilator effect when tested against a histamine (4 micrograms/kg)-induced bronchospasm, produced an anti-anaphylactic effect. The anti-anaphylactic effect of aminophylline varied slightly with the way the animals were immunized and the time at which they were tested. 4 It is concluded that bronchial anaphylaxis in guinea-pigs sensitized with low doses of ovalbumin is a suitable model for the evaluation of anti-anaphylactic properties of drugs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6772264      PMCID: PMC2044278          DOI: 10.1111/j.1476-5381.1980.tb07036.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Mechanics of respiration in unanesthetized guinea pigs.

Authors:  M O AMDUR; J MEAD
Journal:  Am J Physiol       Date:  1958-02

2.  Potentiation of mast cell mediator release by adenosine.

Authors:  D L Marquardt; C W Parker; T J Sullivan
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

3.  Evaluation of oral bronchodilator therapy in asthmatic children. Bronchodilators in asthmatic children.

Authors:  M M Weinberger; E A Bronsky
Journal:  J Pediatr       Date:  1974-03       Impact factor: 4.406

4.  The production of IgE and IgG1 antibodies in guinea-pigs immunized with antigen and bacterial lipopolysaccharides.

Authors:  A Perini; I Mota
Journal:  Immunology       Date:  1973-08       Impact factor: 7.397

5.  Comparison of in vivo and in vitro inhibition of the anaphylactic mechanism by beta-adrenergic stimulants and disodium cromoglycate.

Authors:  E S Assem; A W Richter
Journal:  Immunology       Date:  1971-11       Impact factor: 7.397

6.  The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung.

Authors:  A B Kay; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

7.  Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3',5'-adenosine monophosphate.

Authors:  R P Orange; W G Austen; K F Austen
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

8.  The production of hapten-specific reaginic antibodies in the guinea pig.

Authors:  B B Levine; H Chang; N M Vaz
Journal:  J Immunol       Date:  1971-01       Impact factor: 5.422

9.  Disodium cromoglycate (FPL 670) ('Intal'): a specific inhibitor of reaginic antibody-antigen mechanisms.

Authors:  J S Cox
Journal:  Nature       Date:  1967-12-30       Impact factor: 49.962

Review 10.  Structure and function of human immunoglobulin E.

Authors:  H Bennich; S G Johansson
Journal:  Adv Immunol       Date:  1971       Impact factor: 3.543

View more
  11 in total

1.  Effect of the selective PAF antagonist SM-10661 on an asthmatic model. 2. Effect on antigen-induced dual asthmatic response and infiltration of leukocytes into airways in actively sensitized conscious guinea pigs.

Authors:  T Sugasawa; N Imanishi; S Morooka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  Alternative modes of action of sodium cromoglycate.

Authors:  I M Richards; M Dixon; D M Jackson; K Vendy
Journal:  Agents Actions       Date:  1986-06

3.  Effects of inhibitors of anaphylactic mediators in two models of bronchial anaphylaxis in anaesthetized guinea-pigs.

Authors:  P Andersson
Journal:  Br J Pharmacol       Date:  1982-10       Impact factor: 8.739

4.  Effects of a potassium channel opener (SDZ PCO 400) on guinea-pig and human pulmonary airways.

Authors:  I D Chapman; A Kristersson; G Mathelin; E Schaeublin; L Mazzoni; K Boubekeur; N Murphy; J Morley
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

5.  Influence of tracheal contraction on relaxant effects in vitro of theophylline and isoprenaline.

Authors:  J A Karlsson; C G Persson
Journal:  Br J Pharmacol       Date:  1981-09       Impact factor: 8.739

6.  Receptor-specific mediation by immunoglobulin E of antigen-induced contraction of tracheal and lung parenchymal strips isolated from the guinea pig.

Authors:  F M Graziano; L Gundersen; L A Larson; P Harley; C K Buckner
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

7.  Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease.

Authors:  E Lunell; N Svedmyr; K E Andersson; C G Persson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Antigen-induced bronchial anaphylaxis in actively sensitized guinea-pigs: effect of long-term treatment with sodium cromoglycate and aminophylline.

Authors:  P Andersson; H Bergstrand
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

9.  Attenuation of antigen-induced bronchospasm by fenoterol in the guinea-pig.

Authors:  A G Stewart; M R Fennessy; S J Lewis
Journal:  Agents Actions       Date:  1984-01

10.  Ascaris-induced bronchoconstriction in primates experimentally infected with Ascaris suum ova.

Authors:  I M Richards; R P Eady; D M Jackson; T S Orr; D I Pritchard; K Vendy; E Wells
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.